GroundRules
Browse US Code
Read the original sections, or search by topic.
- 21 U.S.C. § 379d–3a · Hiring authority for scientific, technical, and professional personnel
- 21 U.S.C. § 379d–3b · Strategic Workforce Plan and report
- 21 U.S.C. § 379d–4 · Reporting requirements
- 21 U.S.C. § 379d–5 · Guidance document regarding product promotion using the Internet
- 21 U.S.C. § 379e · Listing and certification of color additives for foods, drugs, devices, and cosmetics
- 21 U.S.C. § 379f · Recovery and retention of fees for freedom of information requests
- 21 U.S.C. § 379g · Definitions
- 21 U.S.C. § 379h · Authority to assess and use drug fees
- 21 U.S.C. § 379h–1 · Fees relating to advisory review of prescription-drug television advertising
- 21 U.S.C. § 379h–2 · Reauthorization; reporting requirements
- 21 U.S.C. § 379i · Definitions
- 21 U.S.C. § 379j · Authority to assess and use device fees
- 21 U.S.C. § 379j–1 · Reauthorization; reporting requirements
- 21 U.S.C. § 379j–11 · Definitions
- 21 U.S.C. § 379j–12 · Authority to assess and use animal drug fees
- 21 U.S.C. § 379j–13 · Reauthorization; reporting requirements
- 21 U.S.C. § 379j–21 · Authority to assess and use generic new animal drug fees
- 21 U.S.C. § 379j–22 · Reauthorization; reporting requirements
- 21 U.S.C. § 379j–31 · Authority to collect and use fees
- 21 U.S.C. § 379j–41 · Definitions
- 21 U.S.C. § 379j–42 · Authority to assess and use human generic drug fees
- 21 U.S.C. § 379j–43 · Reauthorization; reporting requirements
- 21 U.S.C. § 379j–51 · Definitions
- 21 U.S.C. § 379j–52 · Authority to assess and use biosimilar biological product fees
- 21 U.S.C. § 379j–53 · Reauthorization; reporting requirements
- 21 U.S.C. § 379j–61 · Definitions
- 21 U.S.C. § 379j–62 · Authority to assess and use outsourcing facility fees
- 21 U.S.C. § 379j–71 · Definitions
- 21 U.S.C. § 379j–72 · Authority to assess and use OTC monograph fees
- 21 U.S.C. § 379j–73 · Reauthorization; reporting requirements
- 21 U.S.C. § 379k · Information system
- 21 U.S.C. § 379k–1 · Electronic format for submissions
- 21 U.S.C. § 379l · Education
- 21 U.S.C. § 379o · Environmental impact
- 21 U.S.C. § 379r · National uniformity for nonprescription drugs
- 21 U.S.C. § 379s · Preemption for labeling or packaging of cosmetics
- 21 U.S.C. § 379v · Safety report disclaimers
- 21 U.S.C. § 379aa · Serious adverse event reporting for nonprescription drugs
- 21 U.S.C. § 379aa–1 · Serious adverse event reporting for dietary supplements
- 21 U.S.C. § 379dd · Establishment and functions of the Foundation
- 21 U.S.C. § 379dd–1 · Location of Foundation
- 21 U.S.C. § 379dd–2 · Activities of the Food and Drug Administration
- 21 U.S.C. § 381 · Imports and exports
- 21 U.S.C. § 382 · Exports of certain unapproved products
- 21 U.S.C. § 383 · Office of International Relations
- 21 U.S.C. § 384 · Importation of prescription drugs
- 21 U.S.C. § 384a · Foreign supplier verification program
- 21 U.S.C. § 384b · Voluntary qualified importer program
- 21 U.S.C. § 384c · Inspection of foreign food facilities
- 21 U.S.C. § 384d · Accreditation of third-party auditors
- 21 U.S.C. § 384e · Recognition of foreign government inspections
- 21 U.S.C. § 384f · Strengthening FDA and CBP coordination and capacity
- 21 U.S.C. § 384g · Restricting entrance of illicit drugs
- 21 U.S.C. § 387 · Definitions
- 21 U.S.C. § 387a · FDA authority over tobacco products
- 21 U.S.C. § 387a–1 · Final rule
- 21 U.S.C. § 387b · Adulterated tobacco products
- 21 U.S.C. § 387c · Misbranded tobacco products
- 21 U.S.C. § 387d · Submission of health information to the Secretary
- 21 U.S.C. § 387e · Annual registration
- 21 U.S.C. § 387f · General provisions respecting control of tobacco products
- 21 U.S.C. § 387f–1 · Enforcement action plan for advertising and promotion restrictions
- 21 U.S.C. § 387g · Tobacco product standards
- 21 U.S.C. § 387h · Notification and other remedies
- 21 U.S.C. § 387i · Records and reports on tobacco products
- 21 U.S.C. § 387j · Application for review of certain tobacco products
- 21 U.S.C. § 387k · Modified risk tobacco products
- 21 U.S.C. § 387l · Judicial review
- 21 U.S.C. § 387m · Equal treatment of retail outlets
- 21 U.S.C. § 387n · Jurisdiction of and coordination with the Federal Trade Commission
- 21 U.S.C. § 387o · Regulation requirement
- 21 U.S.C. § 387p · Preservation of State and local authority
- 21 U.S.C. § 387q · Tobacco Products Scientific Advisory Committee
- 21 U.S.C. § 387r · Drug products used to treat tobacco dependence
- 21 U.S.C. § 387s · User fees
- 21 U.S.C. § 387t · Labeling, recordkeeping, records inspection
- 21 U.S.C. § 387u · Studies of progress and effectiveness
- 21 U.S.C. § 387v · Reporting on tobacco regulation activities
- 21 U.S.C. § 391 · Separability clause
- 21 U.S.C. § 392 · Exemption of meats and meat food products
- 21 U.S.C. § 393 · Food and Drug Administration
- 21 U.S.C. § 393a · Office of Pediatric Therapeutics
- 21 U.S.C. § 394 · Scientific review groups
- 21 U.S.C. § 395 · Loan repayment program
- 21 U.S.C. § 396 · Practice of medicine
- 21 U.S.C. § 397 · Contracts for expert review
- 21 U.S.C. § 398 · Notices to States regarding imported food
- 21 U.S.C. § 399 · Grants to enhance food safety
- 21 U.S.C. § 399a · Office of the Chief Scientist
- 21 U.S.C. § 399b · Office of Women’s Health
- 21 U.S.C. § 399c · Improving the training of State, local, territorial, and tribal food safety officials
- 21 U.S.C. § 399d · Employee protections
- 21 U.S.C. § 399e · Nanotechnology
- 21 U.S.C. § 399f · Ensuring adequate information regarding pharmaceuticals for all populations, particularly underrepresented subpopulations, including racial subgroups
- 21 U.S.C. § 399g · Food and Drug Administration Intercenter Institutes
- 21 U.S.C. § 399h · National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing
- 21 U.S.C. § 399i · Food and Drug Administration Working Capital Fund
- 21 U.S.C. § 399j · Abraham Accords Office
- 21 U.S.C. § 451 · Congressional statement of findings
- 21 U.S.C. § 452 · Congressional declaration of policy